Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Bilici, AhmetOlmez, Omer FatihSezer, AhmetOksuzoglu, BernaKaplan, Muhammet AliKaradurmus, NuriCubukcu, ErdemSendur, Mehmet A. N.Aksoy, SercanErdem, DilekBasaran, GulCakar, BurcuSeker, MesutArslan, CagatayGoksu, Sema SezginCicin, IrfanGumus, MahmutSelcukbiricik, FatihHarputluoglu, HakanHelvaci, Kaan2022-11-042022-11-0420220732-183Xhttp://hdl.handle.net/11727/8006enginfo:eu-repo/semantics/closedAccessReal-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).conferenceObject4016000863680302513